Search - tctmd.com

Displaying 21 - 40 of 1055

Sort: Relevancy | Date

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Conference News TCT 2024

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

Caitlin E. Cox

October 28, 2024

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

News Conference News EuroPCR 2024

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

Michael O'Riordan

May 28, 2024

News Conference News EuroPCR 2024

PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3

Yael L. Maxwell

May 17, 2024

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

Presentation EuroPCR 2024

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

Presenter: Alexandre Abizaid

May 14, 2024

News Daily News

As US Rollout Begins for Coronary DCBs, Interventionalists Mull Practice Changes

Todd Neale

May 03, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

DCB in STEMI Match DES Through 5 Years: REVELATION

Caitlin E. Cox

March 27, 2024

News Conference News CRT 2024

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

L.A. McKeown

March 14, 2024

News Conference News CRT 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

L.A. McKeown

March 09, 2024

News Daily News

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

L.A. McKeown

March 01, 2024

News Daily News

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

Michael O'Riordan

January 09, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

Advertisement

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

DES Best for In-Stent Restenosis, but DCBs Also Viable

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

As US Rollout Begins for Coronary DCBs, Interventionalists Mull Practice Changes

FDA Approves Bioresorbable Scaffold for BTK Lesions

DCB in STEMI Match DES Through 5 Years: REVELATION

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

Top Endovascular News of 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content